Market Place
Sourcing Support
Merck Initiates Phase 3 Trial For Bomedemstat In Essential Thrombocythemia
27 Aug 2024 //
BUSINESSWIRE
Imago doses first subject in Phase II myelofibrosis treatment trial
22 Dec 2022 //
CLINICALTRIALSARENA
Imago Announces First Participant Dosed Ph 2 Study of Bomedemstat
20 Dec 2022 //
GLOBENEWSWIRE
Imago BioSciences Presents Positive Data from Ongoing Ph2 Study of Bomedemstat
12 Dec 2022 //
GLOBENEWSWIRE
Imago Announces 1st Participant Dosed Ph1 Study of Bomedemstat Combo Venetoclax
30 Nov 2022 //
GLOBENEWSWIRE
Merck bulks up in haematology, buying Imago for $1.35bn
22 Nov 2022 //
PRESS RELEASE
Imago Begins Dosing in Investigator-Sponsored Study of Bomedemstat+Atezolizumab
09 May 2022 //
GLOBENEWSWIRE
Imago BioSciences Announces Completion of Enrollment in PII Study of Bomedemstat
03 May 2022 //
GLOBENEWSWIRE
Imago Bio Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat
12 Dec 2021 //
BUSINESSWIRE
Imago Bio Presents Positive Data of Bomedemstat in Advanced Myelofibrosis
11 Dec 2021 //
PRESS RELEASE
Imago’s Bomedemstat shows Encouraging Clinical Activity in Phase 2 Data
11 Jun 2021 //
BUSINESSWIRE
Imago’s Bomedemstat shows Encouraging Clinical Activity in Phase 2 Data
11 Jun 2021 //
BUSINESSWIRE
Imago BioSciences Expands Ph 2 Trial of Bomedemstat (IMG-7289)
30 Nov 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.